Comparative Pharmacology
Head-to-head clinical analysis: FORADIL CERTIHALER versus SOMOPHYLLIN DF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL CERTIHALER versus SOMOPHYLLIN DF.
FORADIL CERTIHALER vs SOMOPHYLLIN-DF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and blocking adenosine receptors.
One inhalation (12 mcg) twice daily via oral inhalation.
Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding.
Terminal elimination half-life: 3–12 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours), congestive heart failure, and in neonates; also prolonged in elderly and patients with fever or viral illness. Half-life is shorter in smokers (4–5 hours).
After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder.
Renal excretion of unchanged drug: approximately 10%; hepatic metabolism accounts for >90% of elimination; metabolites are excreted renally. Less than 5% eliminated in feces.
Category C
Category C
Bronchodilator
Bronchodilator